Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

By | April 29, 2021
A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of SARS-CoV-2 variants. The team analyzed the impact of potential mutations in the spike RBD on antibody efficacy.